본문 바로가기
KERD
논문KCI 등재

간세포암의 진단과 치료에서 종양표지자의 역할

Roles of Tumor Markers in Diagnosis and Treatment of Hepatocellular Carcinoma

장재영|장영
대한내과학회 (The Korean Association Of Internal Medicine)|2020.02|대한내과학회지 (The Korean Journal of Medicine)|제95권 제1호|pp. 31-35|DOI https://doi.org/10.3904/kjm.2020.95.1.31

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

tumorPIVKA-IICarcinoma hepatocellularBiomakersAlpha-FetoproteinAFP-L3%
주제분류내과학

초록

There are a wide variety of tumor markers for hepatocellular carcinoma (HCC). Studies are ongoing regarding the roles of tumor markers in screening, diagnosis, treatment, and prognostic prediction of HCC. Serum alpha-fetoprotein (AFP) can be very useful for HCC surveillance, prognostic prediction, and treatment response evaluation in high-risk patients with HCC. Other tumor markers such as PIVKA-II and AFP-L3% have also been proven to be effective in HCC diagnosis, follow-up, and prognostic prediction; these markers are increasingly used with serum AFP in clinical trials. However, the roles of tumor markers in surveillance are poorly understood and still controversial, requiring further research. HCC surveillance in at-risk population is a critical issue in management of HCC. Further data regarding the predictive value and cost-effectiveness of tumor markers could facilitate their uses in HCC surveillance.

Abstract

There are a wide variety of tumor markers for hepatocellular carcinoma (HCC). Studies are ongoing regarding the roles of tumor markers in screening, diagnosis, treatment, and prognostic prediction of HCC. Serum alpha-fetoprotein (AFP) can be very useful for HCC surveillance, prognostic prediction, and treatment response evaluation in high-risk patients with HCC. Other tumor markers such as PIVKA-II and AFP-L3% have also been proven to be effective in HCC diagnosis, follow-up, and prognostic prediction; these markers are increasingly used with serum AFP in clinical trials. However, the roles of tumor markers in surveillance are poorly understood and still controversial, requiring further research. HCC surveillance in at-risk population is a critical issue in management of HCC. Further data regarding the predictive value and cost-effectiveness of tumor markers could facilitate their uses in HCC surveillance.

참고문헌 (42)

  1. Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
  2. Kanwal F, "Surveillance for hepatocellular carcinoma : current best practice and future direction", Gastroenterology, 157, pp.54~64 (2019)
  3. van Meer S, "Surveillance for hepatocellular carcinoma is associated with increased survival : results from a large cohort in the Netherlands", J Hepatol, 63, pp.1156~1163 (2015)
  4. Mittal S, "Effectiveness of surveillance for hepatocellular carcinoma in clinical practice : a United States cohort", J Hepatol, 65, pp.1148~1154 (2016)
  5. Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
  6. Kokudo N, "Clinical practice guidelines for hepatocellular carcinoma : The Japan Society of Hepatology 2017(4th JSH-HCC guidelines)2019 update", Hepatol Res, 49, pp.1109~1113 (2019)
  7. Tsukuma H, "Risk factors for hepatocellular carcinoma among patients with chronic liver disease", N Engl J Med, 328, pp.1797~1801 (1993)
  8. Aghoram R, "Alpha-foetoprotein and", or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B, 2012, pp.(9), CD002799~
  9. Singal A, "Meta-analysis : surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis", Aliment Pharmacol Ther, 30, pp.37~47 (2009)
  10. Tzartzeva K, "Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis : a meta-analysis", Gastroenterology, 154, pp.1706~1718 (2018)
  11. European Association for the Study of the Liver, "EASL clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
  12. Gupta S, "Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis", Ann Intern Med, 139, pp.46~50 (2003)
  13. Trevisani F, "Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease : influence of HBsAg and anti-HCV status", J Hepatol, 34, pp.570~575 (2001)
  14. Wong GL, "On-treatment alphafetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir", Hepatology, 59, pp.986~995 (2014)
  15. Kim GA, "Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment", Liver Int, 35, pp.232~239 (2015)
  16. White DL, "The updated model : an adjusted serum alpha-fetoprotein-based algorithm for hepatocellular carcinoma detection with hepatitis C virus-related cirrhosis", Gastroenterology, 149, pp.1986~1987 (2015)
  17. Tayob N, "Improved detection of hepatocellular carcinoma by using a longitudinal alphafetoprotein screening algorithm", Clin Gastroenterol Hepatol, 14, pp.469~475 (2016)
  18. Colli A, "Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma : a systematic review", Am J Gastroenterol, 101, pp.513~523 (2006)
  19. Di Bisceglie AM, "Serum alpha-fetoprotein levels in patients with advanced hepatitis C : results from the HALT-C Trial", J Hepatol, 43, pp.434~441 (2005)
  20. Wong RJ, "Elevated alpha-fetoprotein : differential diagnosis-hepatocellular carcinoma and other disorders", Clin Liver Dis, 19, pp.309~323 (2015)
  21. Imamura H, "Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy", J Hepatol, 38, pp.200~207 (2003)
  22. Ikai I, "Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey", Cancer, 101, pp.796~802 (2004)
  23. Duvoux C, "Liver transplantation for hepatocellular carcinoma : a model including α-fetoprotein improves the performance of Milan criteria", Gastroenterology, 143, pp.986~994 (2012)[DOI]
  24. Notarpaolo A, "Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC", J Hepatol, 66, pp.552~559 (2017)
  25. Mazzaferro V, "Metroticket 2.0 Model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma", Gastroenterology, 154, pp.128~139 (2018)
  26. N'Kontchou G, "Radiofrequency ablation of hepatocellular carcinoma : long-term results and prognostic factors in 235 Western patients with cirrhosis", Hepatology, 50, pp.1475~1483 (2009)
  27. Takayasu K, "Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines", J Hepatol, 56, pp.886~892 (2012)
  28. Llovet JM, "Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma", Clin Cancer Res, 18, pp.2290~2300 (2012)
  29. Zhu AX, "Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib(REACH) : a randomised, double-blind, multicentre, phase 3 trial", Lancet Oncol, 16, pp.859~870 (2015)
  30. Kim YI, "Higher ratio of serum alpha-fetoprotein could predict outcomes in patients with hepatitis B virus-associated hepatocellular carcinoma and normal alanine aminotransferase", PLoS One, 11, pp.e0157299~ (2016)
  31. Liebman HA, "Des-gamma-carboxy(abnormal)prothrombin as a serum marker of primary hepatocellular carcinoma", N Engl J Med, 310, pp.1427~1431 (1984)
  32. Leerapun A, "The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma : evaluation in a United States referral population", Clin Gastroenterol Hepatol, 5, pp.394~402 (2007)
  33. Capurro M, "Glypican-3 : a novel serum and histochemical marker for hepatocellular carcinoma", Gastroenterology, 125, pp.89~97 (2003)
  34. Marrero JA, "Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma", Gastroenterology, 137, pp.110~118 (2009)
  35. Tateishi R, "Diagnostic accuracy of tumor markers for hepatocellular carcinoma : a systematic review", Hepatol Int, 2, pp.17~30 (2008)
  36. Li C, "Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma : a systematic review", Hepatol Res, 44, pp.E11~ (2014)[DOI]
  37. Nakamura S, "Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size", Am J Gastroenterol, 101, pp.2038~2043 (2006)
  38. Sato Y, "Early recognition of hepatocellular carcinoma based on altered profiles of alphafetoprotein", N Engl J Med, 328, pp.1802~1806 (1993)
  39. Taketa K, "A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma", Cancer Res, 53, pp.5419~5423 (1993)
  40. Kumada T, "Clinical utility of lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma : special reference to imaging diagnosis", J Hepatol, 30, pp.125~130 (1999)
  41. Kagebayashi C, "Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis", Anal Biochem, 388, pp.306~311 (2009)
  42. Koike Y, "Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma : a prospective analysis of 227 patients", Cancer, 91, pp.561~569 (2001)

관련 논문AI추천

간세포암종의 진단 및 치료 후 추적 관찰에서 혈청 PIVKA-II의 임상적 효용성김철, 김용수, 김현숙, 문영명, 윤영준, 전재윤, 최혜진, 한광협, 한재용, 한창훈대한간학회 · Clinical and Molecular Hepatology2002 · 제8권 제2002호간세포암의 치료후의 진단과 후속초치에 있어 혈청 PIVKA-II의 효험구금경, 민원기, 박병윤, 이상희, 전사일, 한태진대한임상검사과학회 · 대한임상검사과학회지2011 · 제43권 제4호Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea강현, 배시현, 이준성, 이현웅, Dae Geon Ahn, Hyung Joon Kim, Joon Hyoek Lee, Yong Han Paik대한내과학회 · The Korean Journal of Internal Medicine2016 · 제31권 제1호간세포암의 진단과 재발판정에서 PIVKA-II의 유용성김경규, 김도영, 김자경, 문영명, 백용한, 심명기, 안상훈, 이관식, 전재윤, 한광협대한내과학회 · 대한내과학회지2005 · 제69권 제1호수술 전 알파태아단백치가 높은 간세포암 환자에서 간절제술 후 알파태아단백만을 이용한 추적관찰이 가능한가?김태훈, 서경석, 신우영, 이건욱, 이남준, 전영민대한간학회 · Clinical and Molecular Hepatology2010 · 제16권 제2호간세포암종 진단에 유의한 PIVKA-II 값의 제시 - ROC Curve를 이용하여 -김동우, 김명진, 김정혁, 방기태, 배강우, 서평주, 송일한, 이보한, 정인국대한간학회 · Clinical and Molecular Hepatology2006 · 제12권 제3호

이 간행물의 다른 논문 (5건)

소화기내과 분과전문의 제도 변화차재명pp. 1-5액상 전자담배와 폐질환박소영pp. 6-12혈액투석 유지 환자에서 혈청 인 수치와 동정맥루 기능부전의 상관관계김형종, 최유범, 이미정, 김정현, 최승윤pp. 36-4220대 젊은 남자에서 발병한 췌장암백승호, 임지혜, 이승수, 김지훈, 이준섭, 김명환, 김소현pp. 50-55만성 복통과 철결핍빈혈로 인하여 소화기 질환으로 오인된 발작성 야간혈색소뇨증 1예고지환, 권병진, 박수범, 김형욱, 강대환, 김형진, 최철웅pp. 56-60
원문 보기